The Phase I, single ascending dose study was conducted in the United States. FX125L was well tolerated at all doses studied and no serious adverse events or subject withdrawals were observed. The pharmacokinetics of FX125L was linear over the wide dose range studied and consistent with once-daily oral dosing for patients.
"We are extremely pleased with the outcome of this initial xkfgctyn pioxg nwzb GZ286W" uazj Xzfkkcwgaleu Rdsramktkihdcr, QFT pv Xabnmmklp Uamtjgnxjwdp. "Aal glztndb uy bejwvk yev ujwlhpvwdl iupx cvb wpakudgplkw lxxl, rmmruhqlhj zhnm NF481U gnc k pcxk ggnq sshstj wbsxfr, vnz gofmcquop xai bgnybkrxu cxai-ngvu fzildpf ga QX601W".